A 2-year Follow-up Study to Assess Cognition and Health-related Quality of Life in Participants With Highly-active Relapsing Multiple Sclerosis, Having Participated in the CLARIFY MS Trial (CLARIFY MS Extension)
Latest Information Update: 04 Nov 2025
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CLARIFY MS Extension
- Sponsors Merck KGaA
Most Recent Events
- 17 Sep 2025 Results presented in the EMD Serono Media Release.
- 17 Sep 2025 According to an EMD Serono media release, new four-year data from CLARIFY-MS (n=482) and MAGNIFY-MS (n=270), including their extension studies presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona.
- 12 Sep 2023 Status changed from active, no longer recruiting to completed.